This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006 through 2015. A six-year historic analysis is also provided. The report profiles 207 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Imclone Systems, Inc., Merck KGaA, Novartis AG, Ortho Biotech Products, L.P, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Schering Plough Corporation, Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited, and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CANCER THERAPIES
A GLOBAL STRATEGIC BUSINESS REPORT   MCP-1551


                                         CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-2
      Product Definitions and Scope of Study                            I-3
       Chemotherapy                                                     I-3
       Targeted Therapy                                                 I-3
       Hormonal Therapy                                                 I-3
       Immunotherapy                                                    I-3


 II. EXECUTIVE SUMMARY

  1. Industry Overview                                                  II-1
      Cancer Therapies: A Prelude                                       II-1
       Patent Expiries of Branded Drugs to Trigger Generic  Competition II-1
       New Cancer Therapies Appear Over the Horizon                     II-2
        New Generation Cancer Drugs and Their Area of Use               II-2
       The New Era of Cancer Treatment                                  II-3
        Biotech Cancer Therapies Yet to Overcome  Teething Issues       II-3
         Table 1: Global Market for Biotech-Enabled Cancer Therapies
         (2004 & 2008): Percentage Breakdown of Revenues by
         Application - Hematological, Solid Tumors, and Conditions
         related to Chemotherapy (includes corresponding
         Graph/Chart)                                                   II-3
        Targeted Therapy: The New Frontier of Cancer  Treatment         II-3
         Top Rated Targeted Cancer Therapeutics with the  Potential
          to become Blockbuster Drugs Include:                          II-4
         Oncology Drugs Approved for Use in the Targeted  Cancer
          Therapeutics Sector in the years 2006,  2007, and 2008.       II-4
          Table 2: Molecular Targeted Therapies Worldwide:
          Percentage Breakdown of Molecular Targeted Therapies Under
          Pipeline by Drug Class as of  2006 (includes corresponding
          Graph/Chart)                                                  II-5
        Combination Therapy: A Double Whammy Success                    II-5
       Small Cap Companies: A Target of Private Capital  Financing      II-5
        Drugs (that are both available and under pipeline)
         Developed by the Four Small-Cap Companies                      II-6
        Table 3: Venture Capital Investment (In US$ Millions)  Made
        in Research and Development of Biotechnology for the years
        2004 and 2009 (includes corresponding Graph/Chart)              II-7
       Shifting Therapeutic Preferences                                 II-7
        Table 4: Global Market for Antihormonal Therapy (2005 and
        2014): Percentage Breakdown of Revenues by Drug Class - LHRH
        Analogs, Aromatase Inhibitors, Anti-androgens,
        Anti-estrogens, and Other Hormone  Antagonists(includes
        corresponding Graph/Chart)                                      II-8
       Innovations in Cancer Drug Delivery: A Key Factor  in Product
        Differentiation                                                 II-8
       Personalized Medicine: Gain in Importance                        II-8
      Growth Drivers In a Capsule                                       II-9
       Rise in Cancer Incidences & Access to Modern  Therapeutics
        Foster Growth                                                   II-9
       Demographics & Lifestyles Raise the Risk of Cancer               II-9
        Cancer Prone Sites based on Age                                 II-10
        Table 5: Population of People Aged More than 65 Years  in
        United States for the years 2000, 2010, and 2020  (includes
        corresponding Graph/Chart)                                      II-10
       Unmet Needs Leave Scope for Further Research and  Development    II-10
       Low Entry Barriers in Cancer Research Encourages
        Breakthrough Developments                                       II-10
       Increasing Investments by National Health Authorities            II-11
       Efficiency & High Prices Magnetize Manufacturers                 II-11
       Supportive Cancer Drugs Contribute to Growth                     II-11
       Improved Screening, Diagnosis & Patient Survival Rates
        Trigger Growth                                                  II-11
        Table 6: Global Cancer Diagnostics Market (2004): Breakdown
        of Sales by Geographic Region  (In US$ Billion) (includes
        corresponding  Graph/Chart)                                     II-12
       Molecular Imaging of Cancer: Critical in Improving  Patient
        Outcomes                                                        II-12
       Innovations, Improvements, and Approvals  Propel Growth          II-13
      Growth Restraints                                                 II-13
       High Prices of Targeted Therapies Act as  a Speed Breaker        II-13
        Table 7: Average Costs of Cancer Therapies  in the US as of
        the Year 2005 in US$                                            II-14
       Limited Tumor Specificity and Toxicity                           II-14
       Complicated Treatment Protocols: A Major Stumbling  Block in
        Patient Compliance                                              II-14
       Reduced Smoking                                                  II-14
       Reimbursement and Coverage Remains a Major  Challenge            II-15
      Changes in Reimbursement Policies Influence Market  Prospects     II-15
      Multiple Drug Resistance                                          II-15
      Stringent Regulations Delay Market Approval                       II-16
      Challenges Encountered in Clinical Trials                         II-16
      High Development Costs Retracts Manufacturers  in Developing
       Countries                                                        II-16
      Notes From Across the Globe                                       II-16
       United States                                                    II-16
        Medicare Restructures its Coverage for  Chemotherapy            II-16
        Personalized Care for Cancer Treatment in US                    II-17
        Drugs in Development in the US                                  II-17
         Chemotherapy Drugs Undergoing Trials for  Breast Cancer
          Treatment in United States  (as of 2007)                      II-17
         Hormonal Therapy Drugs Undergoing Trials for  Breast Cancer
          Treatment in United States  (as of 2007)                      II-18
         Targeted Therapy Drugs Undergoing Trials for  Breast Cancer
          Treatment in United States  (as of 2007)                      II-18
        Statistical Findings                                            II-19
         Table 8: US Market for Hospital Cancer Therapies  (2004 and
         2009): Percentage Breakdown of  Revenues by Treatment Type
         - Surgery,  Chemotherapy Drugs, Radiation Therapy,
         Biotechnology-Based Drugs, and Others  (includes
         corresponding  Graph/Chart)                                    II-19

         Table 9: US Demand for Chemotherapy Drugs  (2004 and 2009):
         Percentage Breakdown of Revenues  by Drug Class -
         Alkylating Agents & Related, Antimetabolites & Related,
         Mitotic Inhibitors,  and Others (includes corresponding
         Graph/Chart)                                                   II-19

         Table 10: US Market for Multiple Myeloma (2006): Percentage
         Revenue Breakdown of Leading  Players - Celgene
         Corporation, Millennium Pharmaceuticals, Inc., Ortho
         Biotech,  and Others (includes corresponding  Graph/Chart)     II-20

         Table 11: New Cancer Cases and Deaths  in United States in
         the year 2006 (includes  corresponding Graph/Chart)            II-20

         Table 12: US Market for Cancer Therapies (2004): Percentage
         Revenue Breakdown of Leading Players - Genentech,
         Sanofi-Aventis, AstraZeneca,  Bristol-Myers Squibb, Pfizer,
         Eli Lilly,  Novartis, Roche and Others (includes
         corresponding Graph/Chart)                                     II-21

         Table 13: US Market for Breast Cancer Therapeutics (2006):
         Percentage Breakdown of Revenues by Segment: Cytotoxic
         Therapeutics, Hormonal Therapeutics, and Targeted
         Therapeutics (includes corresponding Graph/Chart)              II-21
       Canada                                                           II-22
        Table 14: New Cases of Cancer Incidences and Deaths  in
        Canada in the year 2006 (includes corresponding Graph/Chart)    II-22
       Australia                                                        II-23
       Asia                                                             II-23
        India                                                           II-23
        Japan                                                           II-24
        Korea                                                           II-24
        Malaysia                                                        II-24
         Table 15: Imports of Cancer Diagnostic and Therapy
         Equipment (2004): Percentage Breakdown of Import Value by
         Country of Origin (includes  corresponding Graph/Chart)        II-24
       Europe                                                           II-24
        Advancements in Breast Cancer Treatment in Europe               II-25
         New Formulations that are Under Clinical Trials                II-25
         Table 16: European Market for Breast Cancer Therapeutics
         (2006): Percentage Breakdown of  Revenues by Drug Class:
         Cytotoxic Drugs, Hormonal Drugs, and Biologics (includes
         corresponding Graph/Chart)                                     II-26
         Drugs Undergoing Trials for Bladder Cancer  Treatment in
          Europe As of 2006                                             II-26
       Latin America                                                    II-27
        Brazil                                                          II-27
        Mexico                                                          II-27
        Argentina                                                       II-27
      Cancer Incidences Worldwide                                       II-28
       Table 17: New Incidences of Liver Cancer (in '000)  Worldwide
       for the years 2008 and 2012                                      II-28

       Table 18: New Incidences of Breast Cancer (in '000)
       Worldwide for the years 2008 and 2012                            II-29
       Table 19: New Incidences of Prostate Cancer (in '000)
        Worldwide for the years 2008 and 2012                           II-30
       Table 20: New Incidences of Bladder Cancer (in '000)
       Worldwide for the years 2008 and 2012                            II-31

  2. Product Overview                                                   II-32
      Cancer: A Major Health Crises in the Modern World                 II-32
       Table 21: Cancer Causes in Developed and Developing Countries
       (2006): Percentage Breakdown by Risk Factors - Diet or
       Nutrition, Infections, Tobacco, and Other Factors  (includes
       corresponding Graph/Chart)                                       II-32
      Types of Cancers                                                  II-32
       Prostate Cancer                                                  II-33
        Key Prostate Cancer Drugs & Companies                           II-33
       Breast Cancer                                                    II-33
        Key Breast Cancer Drugs & Companies                             II-34
       Cervical Cancer                                                  II-34
       Colorectal Cancer                                                II-34
        Key Colorectal Cancer Drugs & Companies                         II-35
       Lung Cancer                                                      II-35
        Key Lung Cancer Dugs & Companies                                II-36
       Renal Cancer                                                     II-36
        Key Renal Cancer Drugs and Companies                            II-36
       Skin Cancer                                                      II-36
       Non-Hodgkin's Lymphoma                                           II-37
       Leukemia                                                         II-37
       Pancreatic Cancer                                                II-37
       Bladder Cancer                                                   II-37
       Endometrial Cancer                                               II-37
      Cancer Therapies: A Review                                        II-37
       Monoclonal Antibodies Open Up A New Era  in Cancer Treatment     II-38
       List of Approved Monoclonal Antibodies Used  in Treating
        Various Cancers                                                 II-38
       Therapeutic Cancer Vaccines: Harnessing the Immune  System to
        Fight Cancer                                                    II-39
        Cancer Vaccine Strategies                                       II-39
         Therapeutic Cancer Vaccine Products Under  Clinical Trials
          as of 2007                                                    II-40
       Gene Therapy                                                     II-40
      Types of Cancer Therapies                                         II-40
       Chemotherapy                                                     II-40
        Chemotherapy Drugs Require Careful Handling                     II-41
        Types of Chemotherapy                                           II-41
        Chemotherapy Drug Classes                                       II-42
        Risks Associated with Chemotherapy                              II-42
        When Chemotherapy Fails                                         II-43
       Targeted Therapy                                                 II-43
        Table 22: Targeted Therapies Market Worldwide (2006):
        Percentage Breakdown of Targeted Therapeutic Drugs Under
        Various Stages of Development (includes corresponding
        Graph/Chart)                                                    II-44
       Hormonal Therapy                                                 II-44
        Hormonal Therapy Strategies                                     II-44
        Drug Classes in Hormone Therapy                                 II-45
         Drugs Used in Hormone Therapy and Their Uses                   II-45
         Side-Effects Associated with the Use of Various  Drugs in
          Hormone Therapy                                               II-46
       Immunotherapy                                                    II-46
        A Primer                                                        II-46
        Immunotherapy Treatment Strategies                              II-47
        Second-Generation Immunotherapies                               II-48
         Table 23: Global Market for Immunotherapy (2007 and 2012):
         Percentage Breakdown of Revenues by Drug  Class -Monoclonal
         Antibodies, Biological Response Modifiers, Vaccines, and
         Other Immunotherapy  Products (includes corresponding
         Graph/Chart)                                                   II-48

  3. Drug Approvals and Clinical Trials                                 II-49
      ABRAXANE Gains Marketing Approval in Korea,  Australia and
       Other Countries                                                  II-49
      GlaxoSmithKline's Cervarix Finds Place in UK National
       Immunization Programme                                           II-49
      Biogen Idec and Elan Commence Clinical Trial of TYSABRI           II-50
      Calistoga Pharmaceuticals Starts Phase I Clinical Trial of
       CAL-101                                                          II-50
      Progen Pharmaceuticals Continues Phase 1 Development  of PG-11047 II-50
      GlaxoSmithKline Receives Conditional EU Approval for
       Marketing Lapatinib                                              II-50
      Roche's Xeloda Gains EU Approval for Use in Colorectal  Cancer
       Treatment                                                        II-50
      Genentech Secures FDA Approval for Avastin                        II-51
      EU Approves Four Biosimilar Versions of Neupogen                  II-51
      Russia Approves Oncophage for Kidney Cancer  Treatment            II-51
      Eisai to Start Clinical Testing of MORAb-028                      II-51
      Threshold Pharmaceuticals Starts Phase I/II Clinical  Trials
       of TH-302                                                        II-51
      AVEO Commences Phase 1b Clinical Study of AV-951  andFOLFOX6      II-51
      GSK's Tykerb Receives USFDA Approval                              II-52
      Seattle Genetics Initiates Phase 1b Clinical Trials of  SGN-40
       with Gemzar and Rituxan                                          II-52
      S*Bio Initiates Phase I Clinical Trials of SB1518                 II-52
      Merck Serono Initiates Phase III Trials of Cladribine             II-52
      BioCurex Receives Patent for RECAF Technology  Applications       II-52
      Chidamide/HBI-8000 Completes Phase I Clinical Trials  in China    II-52
      AVEO Initiates Phase I Trials of AV 299                           II-53
      Exelixis Completes Phase I Trials of XL765                        II-53
      Infinity Pharmaceuticals Starts Phase I Clinical Trial of
       IPI-926                                                          II-53
      Cell Genesys Terminates its VITAL-1 Phase 3 Trial of  GVAX        II-53
      GTx Completes Phase II Clinical Trials of Ostarine                II-53
      Imclone Awaits Approval for Erbitux from US  Medicine Regulator   II-54
      Kuhnil and Daiichi Sankyo Initiate Phase II Clinical  Trial of
       Nimotuzumab                                                      II-54
      Peplin Starts Phase III Clinical Trials of PEP005 Gel             II-54
      ERBITUX Receives Marketing Approval in Japan                      II-54
      Progenics Starts Phase I Clinical Study of PSMA ADC               II-54
      FDA Awards Orphan Drug Designation for the Use of  Stem Cell
       Technology in Bone Marrow  Transplantations                      II-54
      Roche, OSI and Chugai Receive Approval for Tarceva  in Japan      II-55
      Eisai Receives FDA Approval for ONTAK                            II-55
      Genmab Terminates the Development of HuMax-CD4                    II-55
      Teva Pharmaceutical Acquires EU Authorization to  Market
       Neutropenia Drug                                                 II-55
      Novartis' Everolimus Awaits Approvals from US FDA,
       Swissmedic, and EMEA                                             II-55
      Abraxis BioScience, AstraZeneca, and NCCN to Conduct  Anti-
       cancer Drug Studies                                              II-56
      Sanofi-Aventis Receives Japanese Approval for  Taxotere
       Injection                                                        II-56
      Roche's Avastin Bags European Approval for Renal  Cancer
       Treatment                                                        II-56
      Roche Announces European Approval of Herceptin                    II-56
      GSK's Hycamtin Obtains FDA Approval                               II-57
      Avastin Receives European Approval for Breast Cancer  Treatment   II-57
      Roche's Tarceva Obtains European Approval                         II-57
      Roche's NeoRecormon Gains European Approval                       II-57
      Northwest Biotherapeutics' DCVax-Brain Gains Swiss  Approval      II-57
      Alfacell's ONCONASE Receives Orphan Drug  Designation from US     II-58
      Cougar Biotechnology Commences Phase II Trial of  CB7630          II-58
      Lorus Therapeutics Receives Orphan Drug Designation for  its
       LOR-2040                                                         II-58
      Merck Serono Receives EU Approval for mCRC  Treatment With
       Erbitux                                                          II-58
      MGI PHARMA and HELSINN Receive FDA Approval  for Aloxi            II-58
      FDA Grants Approval for Sutent, a Kidney and  Gastrointestinal
       Cancer Drug                                                      II-58
      Wyeth Pharmaceuticals' TORISEL Receives  FDA Approval             II-59
      Dabur Pharma Acquires FDA Approval for Paclitaxel  Injection      II-59
      EUSA's CAPHOSOL Finds Application in Treating  Oral Mucositis     II-59
      European Commission Approves Amgen's Vectibix for  Metastatic
       Colorectal Cancer                                                II-59
      GPC Biotech Starts Phase 2 Trials of Satraplatin plus  with
       Tarceva                                                          II-59
      FDA Approves Vectibix as Treatment for Metastatic  Colorectal
       Cancer                                                           II-60
      FDA Approves IND Indication for CYT-500 of Cytogen                II-60
      FDA Clears Rituxan for New Indications                            II-60
      Epeius Receives BFAD Approval for Expanded Access  Program for
       Rexin- G                                                         II-60
      BioMedicines Initiates Phase 1b Study of Biomed 101               II-61
      Avastin Obtains FDA Approval for Treating Recurrent
       Colorectal Cancer                                                II-61
      Genentech's Herceptin Gains FDA Nod for Treating  Early stage
       Cancer after Surgery                                             II-61
      Epeius Starts Phase I and II Trials of the New Tri-Rex
       Vaccination Protocol                                             II-62
      Sonus Begins Phase 1 Clinical Trial of TOCOSOL  Camptothecin     II-62
      Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist
       Combined with Chemotherapy Regimen                               II-62
      Morphotek's MORAb-009 Receives Orphan Drug  Designation           II-62
      Morphotek's MORAb-003 Receives Orphan Drug Status  from the US
       FDA                                                              II-63
      Morphotek Grants FDA Approval of the IND for  MORAb-009           II-63
      MannKind Receives IND Clearance for MKC1106-PP  Immunotherapy     II-63
      Pharmexa Initiates Phase II trials of GV 1001                     II-64
      Wyeth Pharmaceuticals Declares Discontinuation of  Phase III
       Clinical Trials for Temsirolimus                                 II-64
      OXiGENE Announces Clinical Trials of CA4P                         II-64
      Glaxo SmithKline's Hycamtin Gains FDA Approval for  Treating
       Cervical Cancer                                                  II-64
      Cell Genesys Announces the Initiation of Amplified  Phase I
       Trial of CG0070                                                  II-65
      Genentech's Avastin Receives FDA Approval for  Lung Cancer
       Treatment                                                        II-65
      Vorinostat Acquires FDA Approval for Skin Cancer  Treatment       II-65
      Callisto Launches the First Clinical Trial of Landmark
       Discovery, L-Annamycin for ALL                                   II-65
      Shanghai Sunway Biotech's H101 Receives Marketing  Approval in
       China                                                            II-66
      Northwest Biotherapeutics Gains Patent for CXCR4                  II-66
      Biocon's Cancer Drug Initiates Phase II Trials                    II-67

  4. New Drug Developments and Launches                                 II-68
      GSK Launches Cervarix in Singapore                                II-68
      Abeome Launches New Stem Cell Monoclonal Antibody                 II-68
      Dabur Pharma Launches a New Drug Delivery System,  Nanoxel        II-68
      Epeius Biotechnologies Develops New Targeted  Anti-Cancer Drugs   II-68
      Monash University Scientists Develop siRNA for  Cancer Treatment  II-69
      Cytogen Introduces SOLTAMOX, the First Hormonal  Breast
       Cancer Therapy                                                   II-69

  5. Recent Industry Activity                                           II-70
      Avexa to Acquire Progen Pharmaceuticals                           II-70
      Abraxis Takes Over Platco and Shimoda                             II-70
      WEHI Collaborates with Abbott and Genentech                       II-70
      Novartis Inks a Production Deal with Lonza                        II-70
      Roche to Take Over UK-Based Biotech Company,  Piramed             II-71
      Pfizer Acquires Encysive                                          II-71
      Eden Biodesign Inks a Marketing Services Deal with  Human
       Genome Sciences                                                  II-71
      FivePrime Join Hands with Pfizer for Cancer and  Diabetes
       Research                                                         II-71
      Sanofi-Aventis and Dyax Ink Two Antibody Pacts                    II-72
      Pfizer and AVANT Ink a Global Licensing Agreement for  CDX-110    II-72
      Takeda Inks an Exclusive Partnership Agreement  with Amgen        II-73
      Genentech and Roche Ink a Licensing Agreement with  Glycart       II-73
      Bristol-Myers Squibb to Acquire Kosan Biosciences                 II-73
      Nabi Biopharmaceuticals Collaborates with NIAID                   II-73
      Pfizer to Acquire Serenex                                         II-74
      Morphotek Signs an Agreement with Pivotal BioSciences             II-74
      GE Healthcare Inks a Three-Year Agreement with  Eli Lilly         II-74
      ArQule Signs Two Agreements with Daiichi Sankyo                   II-74
      Circadian Completely Acquires Vegenics Limited                    II-75
      Lpath Inks an Accord with Merck Serono                            II-75
      Topex Expands its Distribution Deal with Therapy  Remarketing     II-75
      Unibioscreen Inks a Partnership Agreement with  Drais
       Pharmaceuticals                                                  II-75
      Avant Immunotherapeutics to Become Celldex  Therapeutics          II-75
      Abraxis Enters into Definitive License Agreements  with
       ProMetic Life Sciences                                           II-76
      Biovest International to Receive US$1.6 Million Funding  for
       Biomedical Research                                              II-76
      Access Completes the Acquisition of Somanta                       II-76
      Clinical Data Inks an Agreement to Take Over  Avalon
       Pharmaceuticals                                                  II-76
      EUSA Pharma Acquires Cytogen Corporation                          II-77
      Oncologic Merges with Triton BioSystems                           II-77
      Eli Lilly to Take Over ImClone Systems                            II-77
      CEL-SCI Establishes a New Manufacturing Unit                      II-77
      ZaBeCor Establishes Biothorpe Pharmaceuticals,  a New Subsidiary  II-78
      Takara Bio Signs a Research Agreement with  a Chinese University  II-78
      Shanghai Roche Expands its MabThera Marketing  Activities         II-78
      Merck Completes the Acquisition of Majority Stake  in Serono      II-78
      Merck Enters into Licensing and Collaboration  Agreement With
       Idera                                                            II-78
      Sanofi-Aventis Inks a Global Licensing Deal with  Oxford
       BioMedica                                                        II-79
      WEHI to Collaborate with Genentech and Roche                      II-79
      AstraZeneca Acquires MedImmune                                    II-79
      Antisoma Enters into a Global Accord with Novartis                II-79
      Sanofi-Aventis and Astellas Pharma to Restructure  their JV
       Operations in Japan                                              II-79
      Biomira Amends its Agreements with Merck                          II-80
      AstraZeneca Takes Over Canadian Biologics Plant                   II-80
      Pfizer to Acquire Coley Pharmaceutical Group                      II-80
      Abraxis Takes Over Watson's Manufacturing Facility                II-80
      Abraxis Takes Over Pfizer's Cruce Davila  Manufacturing Facility  II-81
      Bristol-Myers Squibb to Take Over Adnexus  Therapeutics           II-81
      Merck to Partner with a Florida-based Research Center             II-81
      Organon to Partner with Medarex                                   II-81
      Genzyme to Acquire Bioenvision                                    II-82
      Genentech Inks a Deal with Seattle Genetics                       II-82
      TopoTarget Takes Over Apoxis                                      II-82
      Roche to Acquire CuraGen's Subsidiary                             II-82
      GPC Biotech Inks an Agreement with Yakult                         II-82
      MediGene Acquires Avidex                                          II-82
      Sanofi-Aventis Inks an Agreement with Taiho                       II-83
      Biogen Inks Merger Agreement with Conforma                        II-83
      Roche Signs a Merger Agreement with Ventana                       II-83
      Roche Takes Over THP to Enhance Its Therapeutic  Antibody Profile II-84
      ImClone Systems and Merck Revise ERBITUX  Agreement               II-84
      GSK Invests €500 Million in France                                II-84
      Amgen Takes Over Avidia                                           II-84
      Moores Cancer Center Collaborates with Medarex                    II-84
      ADITUS Medical Forms an Alliance with IGEA                        II-85
      Callisto Opens Site For Phase-II Clinical Trials of  Atiprimod    II-85
      XOMA Inks an Agreement with Attenuon                              II-85
      AstraZeneca Joins Schering to Develop a Novel  Breast Cancer Drug II-85
      Nventa To Procure Hiltonol from Oncovir Incorporated              II-86
      MaxCyte and Medinet Sign an Agreement for  Immuno-Cell Therapy    II-86
      Receptor Acquires Cancer Vaccine 'G17DT'  from Aphton             II-86
      Enzon Collaborates with Santaris for Joint Development  ff
       Novel RNA Antagonists                                            II-87
      Epeius Receives Funding from Lazarex for  Rexin-G Trials         II-87
      Callisto Inks a Deal with M.D. Anderson Cancer  Center            II-87
      AstraZeneca Inks an Agreement with Abraxis  BioScience            II-88
      diaDexus and BVF Establish CFD Therapeutics                       II-88
      Merck to Acquire US Rights for Liposome Vaccine                   II-88
      Genentech Enters Into Alliance with Inotek                        II-89
      AstraZeneca to Take Over KuDOS Pharmaceuticals                    II-89
      Genentech Collaborates with Accelerate Brain  Cancer Cure         II-89
      Sonus and Schering Enter into a Global Licensing  Agreement       II-90
      Abgenix Inks Merger Agreement with Amgen                          II-90
      AstraZeneca and Astex Enter into an Alliance                      II-91
      Pfizer Inks Global License Pact with Coley  Pharmaceutical Group  II-91
      Genzyme Takes Over ILEX Oncology                                  II-91
      Genentech and CGI Enter into an Exclusive Agreement               II-92
      Genzyme to Acquire AnorMED                                        II-92

  6. Focus on Select Players                                            II-93
      Abraxis BioScience, Inc. (USA)                                    II-93
      Amgen, Inc. (USA)                                                 II-93
      AstraZeneca PLC (UK)                                              II-93
      Bayer Schering Pharma (Germany)                                   II-95
      Biogen Idec Inc (USA)                                             II-95
      Bristol-Myers Squibb Company (USA)                                II-96
      Celgene Corporation (USA)                                         II-96
      Cell Therapeutics, Inc. (USA)                                     II-96
      Cephalon, Inc. (USA)                                              II-97
      Chugai Pharmaceutical Co., Ltd. (Japan)                           II-97
      Eli Lilly and Company (USA)                                       II-98
      F. Hoffmann-La Roche Ltd (Switzerland)                            II-98
      Genentech, Inc. (USA)                                             II-99
      Genzyme (USA)                                                     II-99
      GlaxoSmithKline (UK)                                              II-99
      Imclone Systems, Inc (USA)                                        II-101
      Merck KGaA (Germany)                                              II-101
      Novartis AG (Switzerland)                                         II-102
      Ortho Biotech Products, L.P (USA)                                 II-103
      OSI Pharmaceuticals, Inc. (USA)                                   II-103
      Pfizer (USA)                                                      II-103
      Sanofi-Aventis (France)                                           II-104
      Schering Plough Corporation (USA)                                 II-105
      Seattle Genetics, Inc. (USA)                                      II-105
      Takeda Pharmaceutical Company Limited (Japan)                     II-105
      Wyeth (USA)                                                       II-106

  7. Market Perspective                                                 II-107
      Table 24: Global Recent Past, Current & Future Analysis  for
      Cancer Therapies by Type - Targeted Therapy, Chemotherapy,
      Hormone Therapy, and Immunotherapy  Markets Independently
      Analyzed with Annual Sales  Figures in US$ Billion for Years
      2006 through 2015  (includes corresponding Graph/Chart)           II-107

      Table 25: Global Historic Review for Cancer Therapies  by Type -
      Targeted Therapy, Chemotherapy, Hormone  Therapy, and
      Immunotherapy Markets Independently  Analyzed with Annual
      Sales Figures in US$ Billion  for Years 2000 through 2005
      (includes  corresponding Graph/Chart)                             II-107

      Table 26: Global 10-Year Perspective for Cancer  Therapies by
      Type - Percentage Breakdown of  Dollar Sales for Targeted
      Therapy, Chemotherapy,  Hormone Therapy, and Immunotherapy
      for Years 2006, 2009 & 2015 (includes  corresponding
      Graph/Chart)                                                      II-108


III. COMPETITIVE LANDSCAPE